Healthcare -
Biotechnology - NASDAQ - IL
$ 1.98
-0.503 %
$ 90 M
Market Cap
-7.62
P/E
1. INTRINSIC VALUE
Balance Sheet
Entera Bio Ltd.
| Current Assets | 8.97 M |
| Cash & Short-Term Investments | 8.66 M |
| Receivables | 126 K |
| Other Current Assets | 186 K |
| Non-Current Assets | 418 K |
| Long-Term Investments | 0 |
| PP&E | 332 K |
| Other Non-Current Assets | 86 K |
| Current Liabilities | 1.18 M |
| Accounts Payable | 132 K |
| Short-Term Debt | 170 K |
| Other Current Liabilities | 874 K |
| Non-Current Liabilities | 134 K |
| Long-Term Debt | 102 K |
| Other Non-Current Liabilities | 32 K |
EFFICIENCY
Earnings Waterfall
Entera Bio Ltd.
| Revenue | 181 K |
| Cost Of Revenue | 172 K |
| Gross Profit | 9 K |
| Operating Expenses | 9.59 M |
| Operating Income | -9.58 M |
| Other Expenses | -44 K |
| Net Income | -9.54 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Entera Bio Ltd.
| Net Income | -9.54 M |
| Depreciation & Amortization | 46 K |
| Capital Expenditures | -3 K |
| Stock-Based Compensation | 2.56 M |
| Change in Working Capital | 112 K |
| Others | 184 K |
| Free Cash Flow | -6.82 M |
Wall Street Analysts Price Targets
Entera Bio Ltd.
ENTX has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ENTX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Entera Bio Ltd.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025.
globenewswire.com
- 1 month ago
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024.
globenewswire.com
- 3 months ago
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic and fibrotic disorders. The program combines OPKO's proprietary long-acting oxyntomodulin analog (OPK-88006) and Entera's proprietary N-Tab™ technology. Favorable pharmacodynamic, pharmacokinetic and bioavailability data in vivo were reported in September 2024. The companies expect to file an Investigational New Drug application with the U.S. Food and Drug Administration (FDA) later this year.
globenewswire.com
- 3 months ago
Entera Bio to Participate in Upcoming Events
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies in tablet form, today announced that the Company will participate at the following conferences.
globenewswire.com
- 4 months ago
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that it will participate and be available for investor meetings at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held February 11 – 12, 2025 in a virtual format.
globenewswire.com
- 5 months ago
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05.
zacks.com
- 7 months ago
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024.
globenewswire.com
- 7 months ago
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.
zacks.com
- 9 months ago
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera's proprietary N-Tab™ technology. The program is focused on developing the first oral dual agonist GLP-1/glucagon peptide as a potential once-daily treatment for patients with obesity, metabolic and fibrotic disorders. OXM is a naturally occurring peptide hormone found in the small intestine that acts to suppress appetite and induce weight loss.
globenewswire.com
- 9 months ago
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?
Here is how Entera Bio Ltd. (ENTX) and argenex SE (ARGX) have performed compared to their sector so far this year.
zacks.com
- 9 months ago
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Here is how Entera Bio Ltd. (ENTX) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
zacks.com
- 9 months ago
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that management will be participating in the following investor and scientific conferences:
globenewswire.com
- 10 months ago
8. Profile
Summary
Entera Bio Ltd. ENTX
COUNTRY
IL
INDUSTRY
Biotechnology
MARKET CAP
$ 90 M
Dividend Yield
0.00%
Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Contact
Kiryat Hadassah Minrav Building, Jerusalem, 9112002
https://www.enterabio.com
IPO
Date
June 28, 2018
Employees
18
Officers
Dr. Hillel Galitzer M.B.A., Ph.D.
Chief Operating Officer
Ms. Leslie Gautam
Chief Business Officer
Ms. Dana Yaacov-Garbeli CPA
Chief Financial Officer
Dr. Gregory Burshtein Ph.D.
Chief of Research & Development
Ms. Miranda J. Toledano M.B.A.
Chief Executive Officer & Director